Trial results for the HOPE-Genomics intervention, a web-based cancer education tool, were posted on ClinicalTrials.gov on 2025-12-11, involving 465 participants with various carcinomas.
Background
Genomic testing is increasingly vital in cancer care, offering personalized insights into disease prognosis and treatment options. However, understanding complex genomic information can be challenging for patients. Educational tools designed to enhance patient comprehension of their genomic test results and general cancer genomics are crucial for promoting informed decision-making and patient-centered care. The HOPE-Genomics intervention aims to address this need by providing a structured, web-based platform for patient education.
Trial design
This study, designated as Phase NA, enrolled 465 participants. It investigated the effectiveness of the Helping Oncology Patients Explore Genomics (HOPE-Genomics) web-based education tool across several conditions, including Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, and Ovarian Carcinoma. The trial aimed to improve patient knowledge of personal genomic testing results and general cancer and genomics. Participants were assigned to different arms, including Usual Care, Genomics Test Results with HOPE-Genomics, and HOPE-Genomics with Genomics Test Results.
Key results
The trial reported several key measurements:
- Recall Rates of Personal Genomic Results (Count of Participants):
- For 'Arm I (Usual Care)', measurements included 89 participants and 43 participants.
- For 'Arm II (Genomics Test Results, HOPE-Genomics) Plus Arm III (HOPE-Genomics, Genomics Test Results)', measurements included 82 participants and 55 participants.
- For 'Arm III (HOPE-Genomics, Genomics Test Results)', measurements included 83 participants and 48 participants.
- Test-related Distress (scores on a scale, Mean with Standard Deviation):
- For 'Arm I (Usual Care)', the mean score was 11.07 (Standard Deviation 6.29) and another mean score was 12.32 (Standard Deviation 6.83).
- For 'Arm II (Genomics Test Results, HOPE-Genomics)', the mean score was 12.37 (Standard Deviation 6.82) and another mean score was 13.20 (Standard Deviation 7.41).
- For 'Arm III (HOPE-Genomics, Genomics Test Results)', the mean score was 11.17 (Standard Deviation 7.93) and another mean score was 12.48 (Standard Deviation 7.47).
What this means
The posted results provide specific measurements regarding patient recall of personal genomic results and levels of test-related distress across different intervention arms. While the data includes participant counts for recall rates and mean scores with standard deviations for distress, no comparative analyses or statistical significance values were reported. These measurements contribute to understanding patient responses to genomic information and the HOPE-Genomics educational tool, offering insights for future research into patient education strategies in oncology.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04905082, titled "HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics", were posted on 2025-12-11 on clinicaltrials.gov.